IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gerald McMAHON et al.

Title: HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS

Appl. No.: 10/713,201

Filing Date: 11/17/2003

Examiner: Unassigned

Art Unit: 1641

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Final OG Notice from Office of Patent Legal Administration dated August 5, 2003, *Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.*

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/948,090, filed 09/07/2001, now U.S. Patent No. 6,316,479. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the

present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date April 19, 2004

By _____

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 18

Complete if Known	
Application Number	10/713,201
Filing Date	11/17/2003
First Named Inventor	Gerald McMAHON
Group Art Unit	1641
Examiner Name	Unassigned
Attorney Docket Number	034536-0684

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	4,087,535		HEUBACH	05-02-1978	
	A2	4,284,786		KÄMMERER et al.	08-18-1981	
	A3	4,351,841		KÄMMERER et al.	09-28-1982	
	A4	4,965,276		BARTLETT et al.	10-23-1990	
	A5	4,992,271		FERNANDES et al.	02-12-1991	
	A6	5,217,999	A	LEVITZKI et al.	06-08-1993	
	A7	5,268,382	A	BARTLETT et al.	12-07-1993	
	A8	5,314,685	A	TYLE et al.	05-24-1994	
	A9	5,371,099	A	BARTLETT et al.	12-06-1994	
	A10	5,403,858	A	BASTARD et al.	04-04-1995	
	A11	5,476,866	A	KUO et al.	12-19-1995	
	A12	5,494,911	A	BARTLETT et al.	02-27-1996	
	A13	5,514,711	A	KITANO et al.	05-07-1996	
	A14	5,532,259	A	BARTLETT et al.	07-02-1996	
	A15	5,547,971	A	WEITHMANN et al.	08-20-1996	
	A16	5,573,775	A	ROBERTSON et al.	11-12-1996	
	A17	5,610,173	A	SCHWARTZ et al.	03-11-1997	
	A18	5,700,822	A	HIRTH et al.	12-23-1997	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 18

Complete if Known	
Application Number	10/713,201
Filing Date	11/17/2003
First Named Inventor	Gerald McMAHON
Group Art Unit	1641
Examiner Name	Unassigned
Attorney Docket Number	034536-0684

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A19	5,700,823	A	HIRTH et al.	12-23-1997	
	A20	5,783,592	A	SCHWARTZ et al.	07-21-1998	
	A21	5,843,947	A	ROBERT et al.	12-01-1998	
	A22	Re. 36,256	E	SPADA et al.	07-20-1999	
	A23	5,932,602	A	HIRTH et al.	08-03-1999	
	A24	5,958,959	A	HIRTH et al.	09-28-1999	
	A25	5,990,141	A	HIRTH et al.	11-23-1999	
	A26	6,020,372	A	SCHWAB et al.	02-01-2000	
	A27	6,022,884	A	MANTLO et al.	02-08-2000	
	A28	6,184,237	B1	MANTLO et al.	02-06-2001	
	A29	6,187,797	B1	PRUITT et al.	02-13-2001	
	A30	6,316,479	B1	McMAHON et al.	11-13-2001	
	A31	6,333,341	B1	MANTLO et al.	12-25-2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	A32	AU	31010/93	A	ZENECA LIMITED	07-22-1993		
	A33	DE	25 24 929	A1	HOECHST AG	12-16-1976		
	A34	EP	0 359 184	B1	BRISTOL-MYERS SQUIBB COMPANY	03-21-1990		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 18

Complete if Known	
Application Number	10/713,201
Filing Date	11/17/2003
First Named Inventor	Gerald McMAHON
Group Art Unit	1641
Examiner Name	Unassigned
Attorney Docket Number	034536-0684

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	A35	EP	0 413 329	B1	ALCON LABORATORIES, INC.	02-05-1997		
	A36	EP	0 520 722	B1	ZENECA LIMITED	12-30-1992		
	A37	EP	0 522 937	A1	RHONE-POULENC RORER SA	01-13-1993		
	A38	EP	0 537 742	B1	MITSUBISHI CHEMICAL CORPORATION	08-21-1996		
	A39	EP	0 551 230	B1	ROUSSEL-UCLAF	07-19-1995		
	A40	EP	0 607 775	B1	HOECHST AKTIENGESELLSCHAFT	12-09-1998		
	A41	EP	0 607 776	B1	HOECHST AKTIENGESELLSCHAFT	12-09-1998		
	A42	EP	0 607 777	B1	HOECHST AKTIENGESELLSCHAFT	12-09-1998		
	A43	EP	0 645 145	B1	BRISTOL-MYERS SQUIBB COMPANY	03-12-1997		
	A44	EP	0 665 013	B1	AVENTIS PHARMA DEUTSCHLAND GmbH	10-24-2001		
	A45	EP	0 769 296	B1	AVENTIS PHARMA DEUTSCHLAND GmbH	07-04-2001		
	A46	EP	0 804 191	B1	SUGEN, INC. et al.	05-17-2000		
	A47	GB	2 240 104	A	FARMITALIA CARLO ERBA SRL	07-24-1991		
	A48	WO	87/04436	A1	LUNDBLAD	07-30-1987		
	A49	WO	91/17748	A1	HOECHST AKTIENGESELLSCHAFT	11-28-1991		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 18

Complete if Known	
Application Number	10/713,201
Filing Date	11/17/2003
First Named Inventor	Gerald McMAHON
Group Art Unit	1641
Examiner Name	Unassigned
Attorney Docket Number	034536-0684

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	A50	WO	92/02444	A1	THE DOW CHEMICAL COMPANY	02-20-1992		
	A51	WO	92/18481	A1	RHONEPOULENC RORER INTERNATIONAL	10-29-1992		
	A52	WO	92/20642	A1	RHONEPOULENC RORER INTERNATIONAL	11-26-1992		
	A53	WO	92/21641	A1	PFIZER INC.	12-10-1992		
	A54	WO	94/26260	A1	YISSUM RESEARCH DEVELOPMENT COMPANY OF HEBREW UNIVERSITY OF JERUSALEM	11-24-1994		
	A55	WO	95/19169	A2	SUGEN, INC. et al.	07-20-1995		
	A56	WO	95/21613	A1	YISSUM RESEARCH DEVELOPMENT COMPANY OF HEBREW UNIVERSITY OF JERUSALEM	08-17-1995		
	A57	WO	96/33179	A1	SUGEN, INC.	10-24-1996		
	A58	WO	99/10325	A1	GLAXO GROUP LIMITED	03-04-1999		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A59	AAS et al., "Chloropromazine in combination with nitrosourea inhibits experimental glioma growth," *British Journal of Neurosurgery* 8(2):187-192 (1994).	
	A60	ANDREWS et al. (American Veterinary Medicine Association Panel on Euthana), "1993 Report of the AVMA Panel on Euthanasia," *J. American Veterinary Medicine Association* 202(2):229-249 (1993).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/713,201
				Filing Date	11/17/2003
				First Named Inventor	Gerald McMAHON
(use as many sheets as necessary)				Group Art Unit	1641
				Examiner Name	Unassigned
Sheet	5	of	18	Attorney Docket Number	034536-0684

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A61	BARTLETT et al., "Effects of leflunomide on immune responses and models of inflammation," Springer Semin. Immunopathol. 14:381-394 (1993).	
	A62	BARTLETT et al., "Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection," *Agents and Actions* 32:10-21 (1991).	
	A63	BARTLETT et al., "Leflunomide: A novel immunomodulating drug in Nonsteroidal Anti-Inflammatory Drugs" 2nd ed. pp. 349-366, Lewis and Furstk eds., Dekker, NY, (1985).	
	A64	BARTLETT et al., Chemical Abstracts 116:128908, 1992	
	A65	BASERGA et al., "Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal Antibodies," J. of Natl. Cancer Institute 85(16):1327-1333 (1993).	
	A66	BAUDY et al., "Potent Quinoxaline-Spaced Phosphono alpha-Amino Acids of the AP-6 Type as Competitive NMDA Antagonists: Synthesis and Biological Evaluation," J. Med. Chem. 36:331-342 (1993).	
	A67	BILDER et al., "Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells," Am. J. Physiol. 260(Cell Physiol.29):C721-C730 (1991).	
	A68	BIRCHALL et al., "Compositions for killing internal parasites containing 3-teri-alkyl-4-hydroxy-5-halobenzylidene-malononitriles," Chemical Abstracts 88:535 (1978).	
	A69	BRYCKAERT et al., "Inhibition of Platelet-Derived Growth Factor-Induced Mitogenesis and Tyrosine Kinase Activity in Cultured Bone Marrow Fibroblasts by Tyrphostins," Exp. Cell Research 199:255-261 (1992).	
	A70	BUSTELO and BARBACID, "Tyrosine Phosphorylation of the vav Proto-Incogene Product in Activated B Cells," Science 256: 1196-1199 (1992).	
	A71	CARAGLIA et al., "Cytosine arabinoside increases the binding of 125 I-labelled epidermal growth factor and 125 I-transferrin and enhances the in vitro targeting of human tumour cells with anti-(growth factor receptor)mAb," Cancer Immunol. Immunother. 37:150-156 (1993).	
	A72	CARBONI et al., "Cyanocarbon Chemistry. XI. Malononitrile Dimer," J. Am. Chem. Soc. 80:2838-2840 (1958).	
	A73	Cecil Textbook of Medicine, Eds: Wyngaarden, Smith, Bennett, W. B. Saunders p. 2220, (1992).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(use as many sheets as necessary)*				***Complete if Known***	
				Application Number	10/713,201
				Filing Date	11/17/2003
				First Named Inventor	Gerald McMAHON
				Group Art Unit	1641
				Examiner Name	Unassigned
Sheet	6	of	18	Attorney Docket Number	034536-0684

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A74	CHARETTE et al., "Contemporary approaches of chemotherapy," *Neuro-Oncology*, 7(1):135 (1995)	
	A75	CHEN and OKAYAMA, "Calcium Phosphate-Mediated Gene Transfer: A Highly Efficient Transfection System for Stably Transforming Cells with Plasmid DNA," BioTech. 6:632-638 (1988).	
	A76	CHERWINSKI et al., "The Immunosuppressant Leflunomide Inhibits Lymphocyte Progression Through Cell Cycle by a Novel Mechanism," J. Pharmacology and Exp. Therap. 227:460-468 (1995).	
	A77	CHONG et al., "Leflunomide, A Novel Immunomodulatory Agent: In Vitro Analyses of the Mechanism of Immunosuppression," Transplant. Proc. 25:747-749 (1993).	
	A78	CHONG et al., "Leflunomide, A Novel Immunosuppressive Agent," Transplantation 55:1361-1366 (1993).	
	A79	COGHLAN et al., Chemical Abstracts 123:285992, 1995	
	A80	CONN et al., "Purification of a glycoprotein vascular endothelial cell mitogen from a rat glimo-derived cell line," Proc. Natl. Acad. Sci. USA 87:1323-1327 (1990).	
	A81	DAINIPPON PHARM., Chemical Abstracts 72:12709, 1970	
	A82	DATI et al., "Inhibition of c-erB-2 oncogene expression by estrogens in human breast cancer cells," Oncogene 5:1001-1006 (1990).	
	A83	DECKER and LOHMANN-MATTHES, "A quick and simple method for the quantitation of lactate dehydroganse release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," J. Immunol. Methods 115:61-69 (1988).	
	A84	EHRLICH and BOGERT, "Experiments in the Veratrole and Quinoxaline Groups," J. Org. Chem. 12:522 (1947).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 18

Complete if Known	
Application Number	10/713,201
Filing Date	11/17/2003
First Named Inventor	Gerald McMAHON
Group Art Unit	1641
Examiner Name	Unassigned
Attorney Docket Number	034536-0684

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A85	FERRIS et al., "Synthesis of Zuinazoline Nucleosides from Ribose and Anthranilonitrile. Application of Phase-Transfer Catalysis in Nucleoside Synthesis," J. Org. Chem. 44(2):173-178 (1979).	
	A86	FINLAY, "The role of high-dose chemotherapy and stem cell rescue in the treatment of malignant brain tumors," *Bone Marrow Transplantation* 18(Suppl. 3):S1-S5 (1996).	
	A87	FLOEGE et al., "Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo," Kidney International 43S:47-54 (1993).	
	A88	FRY et al., "New insights into protein-tyrosine kinase receptor signaling complexes," Protein Science 2:1785-1797 (1993).	
	A89	FUMIHIRO "Injection Containing Etoposide," Application no. JP60239415 published Nov. 28 1995.	
	A90	GAZIT et al., "Tyrphostins. 1. Synthesis and Biological Activity of Protein Tyrosine Kinase Inhibitors," J. Med. Chem. 32:2344-2352 (1989).	
	A91	GAZIT et al., "Tyrphostins. 2. Heterocyclic and alpha-Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases," J. Med. Chem. 34:1896-1907 (1991).	
	A92	GAZIT et al., "Tyrphostins. 3. Structure-Activity Relationship Studies of a .alpha.-Substituted Benzylidenemalonoitrile 5-S-Aryltyrphostins" J. Med. Chem. 36:3556-3564 (1993).	
	A93	GLANT et al., "Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide," Immunopharmacology 23:105-116 (1992).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 18

Complete if Known	
Application Number	10/713,201
Filing Date	11/17/2003
First Named Inventor	Gerald McMAHON
Group Art Unit	1641
Examiner Name	Unassigned
Attorney Docket Number	034536-0684

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A94	GOTTARDIS et al., "Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumoristatic Action of Tamoxifen," J. Steroid Biochem. 30(1-6):331-314 (1988).	
	A95	GULBINS et al., "Tyrosine Kinase-Stimulated Guanine Nucleotide Exchange Activity of Vav in T Cell Activation," Science 260:822-825 (1993).	
	A96	HALE et al., "Prognostic value of epidermal growth factor receptor expression in cervical carcinoma," J. Clin. Pathol. 46:149-153 (1993).	
	A97	HAMBLETON and MAHON, "Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis" *Agents and Actions* 29:328-332 (1990).	
	A98	HARRIS et al., "Breast Cancer (First of Three Parts)," New England J. of Medicine 327(5):319-328 (1992).	
	A99	HELDIN, "Structural and functional studies on platelet-derived growth factor," EMBO Journal 11:4251-4259 (1992).	
	A100	HOCHBERG et al., "Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study," *Neuro-Oncology* 32(1):45-55 (1997)	
	A101	HOEKSTRA et al., "Differential effects of steurosporine and tyrphostins on receptor tyrosine kinase autophosphorylation and peptide substrate phosphorylation," Experimental Therapeutics from 84th Annual Meeting of American Association for Cancer Research, vol. 34, #2455 (1993).	
	A102	HONEGGER et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," Cell 5:199-209 (1987).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/713,201
				Filing Date	11/17/2003
				First Named Inventor	Gerald McMAHON
				Group Art Unit	1641
(use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	9	of	18	Attorney Docket Number	034536-0684

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A103	HOUCK et al., "The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA," Molecular Endocrinology 5:1806-1814 (1991).	
	A104	ISSIDORIDES and HADDADIN, "Benzofurazan Oxide. II. Reactions with Enolate Anions," J. Org. Chem. 31:4067-4068 (1966).	
	A105	JASCHKE et al., Chemical Abstracts 120:217654, 1994	
	A106	JU et al., "Leflunomide inhibits cytokine-induced DNA synthesis of rabbit synovial cells in culture," Acta Pharmacological Sinica 15:2232-26 (1994).	
	A107	JU et al., "Leflunomide inhibits PAF induced DNA synthesis in rabbit synovial cells and PAF production from rat peritomeal macrophages," *Acta Pharmacological Sinica* 92:90-94 (1994).	
	A108	KAEMMERER et al., Chemical Abstracts 89:109449, 1978	
	A109	KARAMERIS et al., "Expression of Epidermal Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGFR) in Gastric and Colorectal Carcinomas, An Immunohistological Study of 63 Cases," Path. Res. Pract. 189:133-137 (1993).	
	A110	KAUR, "Tyrphostin induced growth inhibitions: correlation with effect on p210.bcr-abl autokinase activity in K562 chronic myelogenous leukemia," Anti-Cancer Drugs 5:213-222 (1994).	
	A111	KIU et al., "Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas," *Neuro-oncology* 25(3):215-220 (1995)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/713,201
				Filing Date	11/17/2003
				First Named Inventor	Gerald McMAHON
				Group Art Unit	1641
(use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	10	of	18	Attorney Docket Number	034536-0684

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A112	KOENDERS et al., "Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study," Breast Cancer Research and Treatment 25:21-27 (1993).	
	A113	KORZENIEWSKI and CALLEWAERT, "An Enzyme-Release Assay for Natural Cytotoxicity," J. Immunol. Methods 64:313 (1983).	
	A114	KOVALENKO et al., "Selective Platelet-derived Growth Factor Receptor Kinase Blockers Reverse sis-Transformation," Cancer Research 54:6106-6114 (1994).	
	A115	KUECHLE et al., "Prevention of Kidney and Skin Graft Rejection in Rats by Leflunomide, a New Immunomodulating Agent," Transplant Proc. 23:1083-1806 (1991).	
	A116	KURPAD et al., Intraarterial O^6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea," *Cancer Chemotherapy and Pharmacology* 39(4):307-316 (1997).	
	A117	LEE and SALEMNICK, "Purine N-Oxides, LXII. 2,4-Dioxophyrido-2,3-d-pyrimidine N-Oxides," J. Org. Chem. 40(24):3608-3610 (1975).	
	A118	LEVITZKI, "Tyrphostins -- Potential Antiproliferative Agents and Novel Molecular Tools," Biochem. Pharm. 40(5):913-918 (1990).	
	A119	LEY and SENG, "Synthesis unter Verwendung von Benzofuroxan," Synthesis 1975:415-422 (1975).	
	A120	LOS MARIO, Chemical Abstracts 102:45926, 1985	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/713,201
				Filing Date	11/17/2003
				First Named Inventor	Gerald McMAHON
(use as many sheets as necessary)				Group Art Unit	1641
				Examiner Name	Unassigned
Sheet	11	of	18	Attorney Docket Number	034536-0684

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A121	LYALL et al., "Tyrphostins Inhibit Epidermal Growth Factor (EGF)-Receptor Tyrosine Kinase Activity in Living Cells and EGF-stimulated Cell Proliferation," J. Bio. Chem., 264:14503-14509 (1989).	
	A122	MALKIN et al., "Phase I study of SU101, a novel signal transduction inhibitor, in recurrent malignant glioma," *Proc Annu. Meet Am. Soc. Clin. Oncol.* 16:A1371 (1997)	
	A123	MANDAL et al., Chemical Abstracts 106:138320, 1987	
	A124	MANTLO et al., Chemical Abstracts 130:352186, 1999	
	A125	MARSHALL, E., "Search for a Killer: Focus Shifts from Fat to Hormones," Science 259:618-621 (1993).	
	A126	MATTAR et al., "Effect of leflunomide active metabolite, A771726, on signal transduction pathways necessary for proliferation," Immunobiology 186(1-2):43 (1992) (abstract).	
	A127	MATTAR et al., "Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide," FEBS Letters 334 (2):161-164 (1993).	
	A128	MCCHESNEY et al., "An Evaluation of Leflunomide in the Canine Real Transplantation Model," Transplantation 57:1717-1722 (1994).	
	A129	MILLAUER et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," Cell 72:835-846 (1993).	
	A130	MOSMANN, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," J. Immunol. Methods 65:55-63 (1983).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 18

Complete if Known	
Application Number	10/713,201
Filing Date	11/17/2003
First Named Inventor	Gerald McMAHON
Group Art Unit	1641
Examiner Name	Unassigned
Attorney Docket Number	034536-0684

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A131	MULLER et al., "BCR First Exon Sequences Specifically Activate the BCR/ABL Tyrosine Kinase Oncogene of Philadelphia Chromosome-Positive Human Leukemias," Mol Cell. Biol. 11:1785-1792 (1991).	
	A132	MYERS et al., See Abs. Attached, Curr. Pharm. Design, 3/5, 1997	
	A133	NICHTERLEIN et al., "Leflunomide (HWA 486) Prolongs Course of Murine Listeriosis," Immunol. Infect. Dis. 4:18-22 (1994).	
	A134	OGAWA et al., "Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats," Agents Actions 31:321-328 (1990).	
	A135	OGAWA et al., "Therapeutic Effects of Leflunomide, a New Antirheumatic Drug, on Glomerulonephritis Induced by the Antibasement Membrane Antibody in Rats," Clin. Immunol. Immunopath. 61:103-118 (1991).	
	A136	OHMICHI et al., "The Tyrosine Kinase Inhibitor Tyrphostin Blocks the Cellular Actions of Nerve Growth Factor," Biochemistry 32:4650-4658 (1993).	
	A137	OSBORNE et al., "Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice," Cancer Research 45:584-590 (1985).	
	A138	OSHEROV et al., "Selective Inhibition of the EGF and Neu receptors by Tyrophostins," J. Cell Biochem. S17A:237 (1993).	
	A139	OSHEROV et al., "Selective Inhibition of the Epidermal Growth Factor and HER2/Neu Receptors by Tyrophostins," J. Bio. Chem. 268:11134-11142 (1993).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 13 of 18

Complete if Known	
Application Number	10/713,201
Filing Date	11/17/2003
First Named Inventor	Gerald McMAHON
Group Art Unit	1641
Examiner Name	Unassigned
Attorney Docket Number	034536-0684

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A140	OZZELO and SORDAT, "Behavior of Tumors Produced by Transplantation of Human Mammary Cells Lines in Athymic Nude Mice," Eur. J. Cancer 16:553-559 (1980).	
	A141	PALOMO COLL, Chemical Abstracts 85:62229, 1976	
	A142	PARK et al., Chemical Abstracts 114:81672, 1991	
	A143	PATTERSON et al., "3-Carboxy-5-methyl-N-4-(trifluoromethyl)phenyl-4-isoxazolecarboxamide, a New Prodrug for the Antiarthritic Agent 2-Cyano-3-hydroxy-N-4-(trifluoromethyl)phenyl-2-butenamide," J. Med. Chem. 35:507-520 (1992).	
	A144	PETERSON and BARNES, "Genistein and Biochanin A Inhibit the Growth of Human Prostate Cancer Cells but not Epidermal Growth Factor Receptor Tyrosine Autophosphorylation," The Prostate 22:335-345 (1993).	
	A145	PIGOTT et al., "Expression of epidermal growth factor receptor in human glioblastoma multiforme," Brit. J. of Neurosurgery 7:261-265 (1993).	
	A146	PLATE et al., "Platelet-Derived Growth Factor Receptor-beta is Induced during Tumor Development and Upregulated during Tumor Progression in Endothelial Cells in Human Gliomas," Laboratory Investigation 4:529-534 (1992).	
	A147	PLATE et al., "Up-Regulation of Vascular Endothelial Growth Factor and Its Cognate Receptors in a Rat Glioma Model of Tumor Angiogenesis," Cancer Research 53:5822-5827 (1993).	
	A148	PLATE et al., "Vascular endothelial growth factor is a potential tumour angiogeneis factor in human gliomas in vivo," Nature 359:845-848 (1992).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/713,201
				Filing Date	11/17/2003
				First Named Inventor	Gerald McMAHON
				Group Art Unit	1641
(use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	14	of	18	Attorney Docket Number	034536-0684

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A149	PLOWMAN et al., "Preclinical antitumor activity of temozolomide in mice: Efficacy against human brain tumor xenografts and synergism with 1,3-Bis(2-chloroethyl)-1-nitrosourea" *Cancer Research* 54(14):3793-3799 (1994)	
	A150	POLLACK et al., "Response of malignant glioma cell lines to epidermal growth factor and platelet-derived growth factor in a serum-free medium," J. Neurosurg. 73:106-112 (1990).	
	A151	PRUITT et al., Chemical Abstracts 134:163023, 2001	
	A152	REN et al., "Identification of a Ten-Amino Acid Proline-Rich SH3 Binding Site," Science 259:1157-1161 (1993).	
	A153	RENDU et al., "Inhibition of Platelet Activation by Tyrosine Kinase Inhibitors," Biochem. Pharm. 44(5):881-888 (1992).	
	A154	ROBERT et al., Chemical Abstracts 124:202306, 1996	
	A155	ROSEN et al., "A phase I/II study of SU101 in patients with ovarian, prostate, and non-small cell lung cancers," *Proc. Annu. Meet. Am. Soc. Clin. Oncol.* 16:A739 (1997).	
	A156	ROSENTHAL et al., "Conditioned Medium from Mouse Sarcoma 180 Cells Contains Vascular Endothelial Growth Factor," Growth Factors 4:53-59 (1990).	
	A157	ROSS, "The pathogenesis of atherosclerosis: a perspective for the 1990s," Nature 362:801-809 (1993).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/713,201
				Filing Date	11/17/2003
				First Named Inventor	Gerald McMAHON
				Group Art Unit	1641
(use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	15	of	18	Attorney Docket Number	034536-0684

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A158	RUSCH et al., "Differential Expression of the Epidermal Growth Factor Receptor and Its Lgands in Primary Non-Small Cell Lung Cancers and Adjacent Benign Lung," Cancer Research 53:2379-2385 (1993).	
	A159	RYGAARD and POVLSEN, "Heterotransplantation of a Human Malignant Tumour to Nude Mice," Acta Path. Microbiol. Scand. 77:758-760 (1969).	
	A160	RYING et al., Chemical Abstracts 127:121701, 1997	
	A161	SCHORLEMMER et al., "Prolongation of Allogeneic Transplanted Skin Grafts and Induction of Tolerance by Leflunomide, A New Immunosuppressive Isoxazol Derivative," Transplant. Proc. 25:763-767 (1993).	
	A162	SCHORNAGEL et al., "Synthesis and Evaluation of 2,4-Diaminoquinazoline Antioflates with Activity Against Methotrexate-Resistant Human Tumor Cells," Biochem. Pharm. 33(20):3251-3255 (1984).	
	A163	SCHWAB et al., Chemical Abstracts 126:325499, 1997	
	A164	SCOTT et al., "p185.HER2 Signal Transduction in Breast Cancer Cells," J. Bio. Chem. 266(22):14300-14305 (1991).	
	A165	SEIBERT et al., "Clonal Variation of MCF-7 Breast Cancer Cells in Vitro and in Athymic Nude Mice," Cancer Research 43:2223-2239 (1983).	
	A166	SHAFIE and GRANTHAM, "Role of Hormones in Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted into Athymic Nude Mice," J. Natl. Cancer Institute 67(1):51-56 (1981).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/713,201
				Filing Date	11/17/2003
				First Named Inventor	Gerald McMAHON
(use as many sheets as necessary)				Group Art Unit	1641
				Examiner Name	Unassigned
Sheet	16	of	18	Attorney Docket Number	034536-0684

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A167	SHWEIKI et al., "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," Nature 359:843-845 (1992).	
	A168	SKEHAN et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," J. Natl. Cancer Inst. 82:1107-1112 (1990).	
	A169	TALMADGE and TWARDZIK, "Role of Cytokines in Inflammation and Autoimmunity," Agents and Actions 35S:135-141 (1991).	
	A170	THOENES et al., "Leflunomide (HWA 486) Inhibits Experimental Autoimmune Tubulointerstitial Nephritis in Rats," Int. J. Immunopharmacol. 11:921-929 (1989).	
	A171	UENO et al., "Inhibition of PDGF beta Receptor Signal Transduction by Coexpression of a Truncated Receptor," Science 252:844-852 (1991).	
	A172	ULRICHS et al., "Suppression of Natural Xenophile Antibodies With the Novel Immunomodulating Drug Leflunomide," Transplant Proc. 24:718-719 (1992).	
	A173	VAN der WALL et al., "High-dose chemotherapy regimens for solid tumors," *Cancer Treatment Reviews* 21(2):105-132 (1995)	
	A174	Van UMMERSEN et al., "A phase I trial of SU101 in patients with solid tumors," *Proc. Annu. Meet. Am. Soc. Clin. Oncol.* 16:A740 (1997)	
	A175	WADA et al., "Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins," Oncogene 5:489-495 (1990).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/713,201
				Filing Date	11/17/2003
				First Named Inventor	Gerald McMAHON
				Group Art Unit	1641
(use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	17	of	18	Attorney Docket Number	034536-0684

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A176	WALTENBERGER et al., "Different Signal Transduction Properties of KDR and Flt1, Two Receptors for Vascular Endothelial Growth Factor," J. Biol. Chem. 269:26988-26995 (1994).	
	A177	WARRI et al., "Estrogen Suppression of erbB2 Expression is Associated with Increased Growth Rate of ZR-75-1 Human Breast Cancer Cells In Vitro and in Nude Mice," Int. J. Cancer 49:616-623 (1991).	
	A178	WEDGE et al., "O^6-benzylguanine enhances the sensitivity of a glioma xenograft with low O^6-axlkylguanine-DNA alkyltransferase activity to temozolomide and BCNU," *British Journal of Cancer* 73(9):1049-1052 (1996).	
	A179	WEITHMANN et al., "Effect of leflunomide on constitutive and inducible pathways of cellular eicosanoid generation," Agents Actions 41:164-170 (1994).	
	A180	WHITE, Chemical Abstracts 111:227133, 1989	
	A181	WILLIAMS et al., "Immunosuppressive Effects of Leflunomide in a Cardiac Allograft Model," Transplantation Proc. 25:745-746 (1993).	
	A182	WILLIAMS et al., "Leflunomide in Experimental Transplantation," Transplantation 57:1223-1231 (1994).	
	A183	XIAO et al., "Effect of Leflunomide in Control of Acute Rejection in Hamster-to-Rat Cardiac Xenografts," Transplantation Proceedings 26:1263-1265 1994).	
	A184	XIAO et al., "Leflunomide Controls Rejection in Hamster to Rat Cardiac Xenografts," Transplantation 58:828-834 (1994).	
	A185	YAISH et al., "Blocking of EGF-Dependent Cell Proliferation by EGF Receptor Kinase Inhibitors," Science 242:933-935 (1988).	
	A186	YONEDA et al., "The Antioproliferative Effects of Tyrosine Kinase Inhibitors Tyrphosins on a Human Squamous Cell Carcinoma in Vitro and in Nude Mice," Cancer Research 51:4430-4435 (1991).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 18 of 18

Complete if Known	
Application Number	10/713,201
Filing Date	11/17/2003
First Named Inventor	Gerald McMAHON
Group Art Unit	1641
Examiner Name	Unassigned
Attorney Docket Number	034536-0684

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A187	ZEILLINGER et al., "EGF-R and Steroid Receptors in Breast Cancer: A Comparison with Tumor Grading, Tumor Size, Lymph Node Involvement, and Agent" Clin. Biochem. 26:221-227 (1993)	
	A188	ZIELINSKI et al., "Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers," Agents Actions 38:(Special Conference Issue) C80-C82 (1993).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.